INMED PHARMACEUTICALS INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $618.68 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $837.26K, a 547.12% increase year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $113.84K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$58.35K, a 116.23% decline year-over-year.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$274.07K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$806.53K.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$811.60K, a 334.10% decline from fiscal 2021.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $346.69K, a 25.83% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $467.39K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $837.26K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $951.09K derived: sum of 2 quarters · filed 2026-09-09 | $892.75K derived: sum of 3 quarters · filed 2026-09-09 | $618.68K S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | $113.84K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $55.49K derived: sum of 2 quarters · filed 2026-07-02 | -$218.58K S-4 · filed 2026-07-02 | -$89.19K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-12-31 | -$58.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$332.41K 10-Q · filed 2026-02-11 | -$203.03K derived: sum of 3 quarters · filed 2026-09-09 | -$269.65K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-09-30 | -$274.07K 10-Q · filed 2025-11-06 | -$144.68K derived: sum of 2 quarters · filed 2026-09-09 | -$211.31K derived: sum of 3 quarters · filed 2026-09-09 | $148.31K derived: sum of 4 quarters · filed 2026-09-09 | ||
| 2025-06-30 | $129.38K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $62.76K derived: sum of 2 quarters · filed 2026-09-09 | $422.38K derived: sum of 3 quarters · filed 2026-09-09 | -$220.02K S-4/A · filed 2026-09-09 | -$249.73K 10-K · filed 2025-09-23 | |
| 2025-03-31 | -$66.62K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $292.99K derived: sum of 2 quarters · filed 2026-07-02 | -$349.40K S-4 · filed 2026-07-02 | -$244.30K 10-Q · filed 2025-05-12 | $121.33K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-12-31 | $359.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$282.78K 10-Q · filed 2026-02-11 | $187.95K derived: sum of 3 quarters · filed 2026-07-02 | $83.61K derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-09-30 | -$642.39K 10-Q · filed 2025-11-06 | -$171.66K derived: sum of 2 quarters · filed 2026-07-02 | -$276.00K derived: sum of 3 quarters · filed 2026-07-02 | -$34.63K derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-06-30 | $470.73K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $366.39K derived: sum of 2 quarters · filed 2026-07-02 | $607.77K derived: sum of 3 quarters · filed 2026-07-02 | $45.28K S-4 · filed 2026-07-02 | ||
| 2024-03-31 | -$104.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $137.04K derived: sum of 2 quarters · filed 2025-05-12 | -$425.45K 10-Q · filed 2025-05-12 | -$646.63K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $241.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$321.11K 10-Q · filed 2025-02-12 | -$542.29K derived: sum of 3 quarters · filed 2025-02-12 | -$618.76K derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-09-30 | -$562.48K 10-Q · filed 2024-11-14 | -$783.67K derived: sum of 2 quarters · filed 2024-11-14 | -$860.14K derived: sum of 3 quarters · filed 2024-11-14 | -$1.21M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$221.19K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$297.66K derived: sum of 2 quarters · filed 2024-09-30 | -$647.27K derived: sum of 3 quarters · filed 2024-09-30 | -$806.53K 10-K · filed 2024-09-30 | ||
| 2023-03-31 | -$76.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$426.08K derived: sum of 2 quarters · filed 2024-02-13 | -$585.34K 10-Q · filed 2023-05-15 | -$1.20M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-12-31 | -$349.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$508.87K 10-Q · filed 2024-02-13 | -$1.13M derived: sum of 3 quarters · filed 2024-02-13 | -$1.62M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-09-30 | -$159.26K 10-Q · filed 2023-11-14 | -$775.73K derived: sum of 2 quarters · filed 2023-11-14 | -$1.27M derived: sum of 3 quarters · filed 2023-11-14 | -$501.63K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$616.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | -$1.11M derived: sum of 2 quarters · filed 2023-09-29 | -$342.37K derived: sum of 3 quarters · filed 2023-09-29 | -$811.60K 10-K · filed 2023-09-29 | ||
| 2022-03-31 | -$491.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | $274.10K derived: sum of 2 quarters · filed 2023-05-15 | -$195.13K 10-Q · filed 2023-05-15 | $387.45K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $765.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $296.44K 10-Q · filed 2023-02-17 | $879.01K derived: sum of 3 quarters · filed 2023-02-17 | $346.15K derived: sum of 4 quarters · filed 2023-02-17 | ||
| 2021-09-30 | -$469.23K 10-Q · filed 2022-11-14 | $113.35K derived: sum of 2 quarters · filed 2022-11-14 | -$419.51K derived: sum of 3 quarters · filed 2022-11-14 | -$283.26K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $582.58K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $49.71K derived: sum of 2 quarters · filed 2022-09-23 | $185.97K derived: sum of 3 quarters · filed 2022-09-23 | $346.69K 10-K · filed 2022-09-23 | ||
| 2021-03-31 | -$532.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | -$396.61K derived: sum of 2 quarters · filed 2022-05-13 | -$235.89K 10-Q · filed 2022-05-13 | $8.13K derived: sum of 4 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $136.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $296.97K 10-Q · filed 2022-02-14 | $540.99K derived: sum of 3 quarters · filed 2022-02-14 | $764.09K derived: sum of 4 quarters · filed 2022-02-14 | ||
| 2020-09-30 | $160.72K 10-Q · filed 2021-11-10 | $404.74K derived: sum of 2 quarters · filed 2021-11-10 | $627.84K derived: sum of 3 quarters · filed 2021-11-10 | $775.79K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $244.02K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $467.12K derived: sum of 2 quarters · filed 2021-09-24 | $615.07K derived: sum of 3 quarters · filed 2021-09-24 | $467.39K 10-K · filed 2021-09-24 | ||
| 2020-03-31 | $223.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $371.05K derived: sum of 2 quarters · filed 2021-05-13 | $223.37K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $147.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $269.00 10-Q · filed 2021-02-11 | ||||
| 2019-09-30 | -$147.68K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |